New York: Sanofi Pasteur, the vaccine business of the Paris-based drug giant Sanofi-Aventis, has awarded business for half its product lines, including its candidate 5-in-1 vaccine Pentacel, to Publicis Public Relations.
The agreement is a joint collaboration between Manning Selvage & Lee and Publicis Consultants PR, Publicis' newly rebranded PR offering. The task also includes Adacel, the new Tdap (tetanus, diphtheria, acellular pertussis) vaccine for adolescents and adults.
Susan Watkins, PR manager for the pediatric and pertussis lines at Sanofi Pasteur, said the decision came after a three-month review during which three other agencies were considered. Watkins did not disclose the size of the account.
Pentacel, the company's 5-in-1 vaccine for children, received backing from a Food and Drug Administration advisory panel last month, boosting its chances of gaining full approval.
The vaccine would decrease the number of shots a child would need during its first 18 months from 23 to 16. Pentacel is designed to prevent tetanus, diphtheria, pertussis, polio, and Haemophilus influenzae type b.
"We believe the marketplace is interested in combination vaccines because of all the vaccines on children's schedules," Watkins said. "We have high expectations, we are looking forward to hearing from the FDA, and Publicis will be helping us along the way."